Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from CRL

FDA Rejects Acer Therapeutics - Relief Therapeutics' Urea Cycle Disorder Candidate

The FDA issued a Complete Response Letter regarding the marketing application for Acer Therapeutics Inc (NASDAQ:ACER) and its collaboration partner, Relief Therapeutics Holding SA's (OTC:RLFTF) ACER-001 (sodium phenylbutyrate), for urea cycle disorders (UCDs). The CRL states: "[The FDA's] field investigator could not complete inspection of [Acer's third-party contract packaging manufacturer] because the facility was not ready…

Stocks to Avoid: 3 Companies That Recently Issued Profit Warnings

Stocks to Avoid: 3 Companies That Recently Issued Profit Warnings

The persistent macroeconomic and geopolitical headwinds continue to keep the stock market under immense pressure. Amid the uncertainties surrounding the stock market, it could be wise to avoid shares of Charles River Laboratories International (CRL), Credit Suisse Group AG (CS), and The Scotts Miracle-Gro (SMG) as these hard-hit companies have…

Does Charles River Laboratories International Deserve a Place in Your Portfolio?

Does Charles River Laboratories International Deserve a Place in Your Portfolio?

The shares of Charles River Laboratories (CRL) have plunged in price despite the company’s solid results. So, can they rebound by the company leveraging its broad portfolio of products and services? Read on. Let’s find out.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer

The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ:CHRS) toripalimab application for advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). NPC is a rare tumor of the head and neck which originates in the nasopharynx, located behind the nose and above the back of the throat. The…

As Expected, FDA Rejects Axsome Therapeutics' Migraine Candidate

The FDA has issued a Complete Response Letter (CRL) to Axsome Therapeutics Inc's (NASDAQ:AXSM) AXS-07 for the acute treatment of migraine. The CRL did not identify or raise any concerns about the clinical efficacy or safety data in the NDA, and the FDA did not request any new clinical trials to support the approval…

Charles River Buys Contract Vivarium Research Services Firm In $295M Deal

Charles River Laboratories International Inc (NYSE: CRL) has acquired Explora BioLabs Holdings Inc, a provider of contract vivarium research services,

FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia

The FDA has issued a complete response letter (CRL) to Akebia Therapeutics Inc's (NASDAQ:AKBA) marketing application (NDA) for vadadustat for anemia due to chronic kidney disease (CKD). Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. The FDA issues a CRL to indicate that the review cycle for an application is complete…

inkl

Read news from The Economist, FT, and more,
with one subscription

FDA Declines To Approve AstraZeneca's Asthma Treatment For Chronic Nasal Condition

FDA Declines To Approve AstraZeneca's Asthma Treatment For Chronic Nasal Condition

The FDA has declined to approve AstraZeneca Plc's (NASDAQ:AZN) asthma medicine, Fasenra (benralizumab), to treat chronic rhinosinusitis with nasal polyps, a condition characterized by benign growths that cause pain and stuffiness. The FDA has issued a complete response letter following AstraZeneca's application to extend the use of Fasenra and requested additional clinical data…

CRL Foods secures £410k investment to add production lines at Newcastle base

CRL Foods secures £410k investment to add production lines at Newcastle base

The supplier to global food brands and UK supermarkets said it secured a number of "transformational" contracts

Birmingham Post

Charles River's Q4 Earnings Beats Street Expectation, Reaffirms FY22 Outlook

Charles River's Q4 Earnings Beats Street Expectation, Reaffirms FY22 Outlook

Charles River Laboratories International Inc's (NYSE: CRL)

Organisations

AstraZeneca Plc

Credit Suisse Group AG

Charles River Laboratories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

127,179 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play